Imricor Medical Systems Inc (ASX:IMR)
A$ 0.49 -0.03 (-5.77%) Market Cap: 123.67 Mil Enterprise Value: 137.83 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 18/100

Q4 2019 Imricor Medical Systems Inc Earnings Call Transcript

Jan 29, 2020 / 10:00PM GMT
Release Date Price: A$1.41 (+7.35%)
Steve Wedan
Imricor Medical Systems, Inc. - CEO, President & Chairman of Board

(technical difficulty)

Lori Milbrandt
Imricor Medical Systems, Inc. - CFO & VP of Finance

Thanks, Steve. As a reminder, all numbers are unaudited and in U.S. dollars.

Net cash outflows from operating activities was $2.242 million for the fourth quarter, which was significantly higher than the third quarter as the company continued to build inventory in preparation for CE mark approval. Cash outflows from investing were $28,000. Financing cash outflows were $608,000, consisting primarily of the payment of remaining IPO transaction costs.

Our cash balance of $5.049 million was less than the prospective amount of $7.954 million due to the reductions in revenue due to the delay in CE mark, the cancellation of the NIH contract and the delay in IP license revenue. These reductions were partially offset by lower than forecast accounts receivable, inventory purchases and operational spending.

I'll hand it back over to Steve now to provide you with an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot